비교리스트

 카트 문의
시장보고서
상품코드
1289650

혈액 악성 종양 검사 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측(2017-2027년), 성분별, 기술별, 치료 적응증별, 최종사용자별, 기업별, 지역별 세분화

Hematologic Malignancies Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Component, By Technique, By Therapeutic Indication, By End User, By company and By Region
발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 114 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 혈액 악성 종양 검사 시장은 2023-2027년 예측 기간 동안 괄목할 만한 성장을 이룰 것으로 예상됩니다.

혈액암 발생 건수 증가와 광범위한 기술 개발 등 주요 요인이 시장 성장을 견인하고 있습니다. 혈액암은 혈액, 골수 및 림프절에 영향을 미치는 암입니다. 백혈병, 림프종, 골수종은 일반적인 혈액암 유형입니다. 혈액암 검사는 혈액암을 진단하는 데 도움이 되는 의료 검사 방법입니다. 기타 시장 성장 요인으로는 연구개발 활동 증가, 정부 보조금 증가, 개인 맞춤형 의료에 대한 관심 증가, 환자 및 의료진의 인식 증가, 고령화 사회 도래, 무기적 성장 전략 채택 증가, 제품 출시 증가, 신흥 하위 시장에 대한 큰 잠재력을 꼽을 수 있습니다.

혈액 관련 질환의 발생률 증가

백혈병, 림프종, 골수종과 같은 혈액 관련 질환의 증가는 전 세계적으로 시장 성장을 견인하고 있습니다. 미국 암협회에 따르면, 미국에서는 약 3분의 1이 백혈병, 림프종, 골수종 진단을 받고 있습니다. 혈액암 환자 수가 증가하면서 혈액암의 조기 발견과 치료의 필요성이 증가하면서 시장 성장을 견인하고 있습니다. 혈액암은 전 세계에서 5번째로 흔한 악성 종양으로 암으로 인한 사망의 두 번째 주요 원인입니다. 예를 들어, 전 세계적으로 연간 30만 명 이상이 백혈병, 40만 명 이상이 림프종 진단을 받고 있습니다.

기술의 진화와 연구개발 활동의 활성화

헬스케어 분야의 신기술의 발전은 시장 성장을 가속화하고 있습니다. 디지털 PCR, 차세대 염기서열 분석기, 세포 유전학 등 혁신적인 신기술이 도입되면서 시장 성장에 힘을 실어주고 있습니다. 이러한 개발로 인해 치료 비용과 시간을 최소화하고 인간의 삶의 질을 향상시킬 수 있게 되었습니다. 또한, 연구개발 활동이 활발해지면서 시장 성장에 힘을 보태고 있습니다.

무기적 성장 전략의 채택 증가

M&A, 협업, 파트너십과 같은 무기적 성장 전략의 증가와 시장 기업의 제품 발표가 증가하면서 시장 성장을 촉진하고 있습니다. 예를 들어, 2021년 Natera, Inc.와 Personalis, Inc.는 Personis의 NeXT 종양 프로파일링 및 진단 제품과 Natera의 개인화 ctDNA 플랫폼 Signatera를 결합하여 치료 모니터링 및 분자 잔존 병변 평가를 위한 개인맞춤형 종양학 분야에서 협력하고 있습니다. 또한, 2018년 애보트는 혈액학 시스템을 통합한 h시리즈를 출시하여 임상 검사실에 많은 변화를 가져왔습니다.

이용 가능한 커스터마이징

주어진 시장 데이터를 바탕으로 TechSci Research는 기업의 특정 요구에 따라 맞춤형을 제공합니다. 본 보고서는 다음과 같은 커스터마이징이 가능합니다.

기업 정보

  • 추가 시장 참여자(최대 5명)에 대한 자세한 분석 및 프로파일링

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 혈액 악성 종양 검사 세계 시장에 대한 COVID-19의 영향

제5장 고객의 소리

제6장 임상시험 분석

제7장 혈액 악성 종양 검사 세계 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 컴포넌트별(키트/서비스)
    • 기술별(차세대 시퀸싱(NGS), 중합효소 연쇄 반응(PCR), FISH(Fluorescent In Situ Hybridization), 면역조직화학(IHC), 기타)
    • 치료 적응증별(백혈병, 림프종, 다발성 골수종, 골수 증식성 신생물, 기타)
    • 최종사용자별(병원·클리닉, 진단 연구소, 학술·연구기관, 기타)
    • 기업별(2021년)
    • 지역별
  • 시장 맵

제8장 북미의 혈액 악성 종양 검사 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 컴포넌트별
    • 기술별
    • 치료 적응증별
    • 최종사용자별
    • 국가별
  • 북미 국가별 분석
    • 미국
    • 캐나다
    • 멕시코

제9장 유럽 혈액 악성 종양 검사 시장 전망

  • 시장 규모와 예측
    • 금액 기준
  • 시장 점유율과 예측
    • 컴포넌트별
    • 기술별
    • 치료 적응증별
    • 최종사용자별
    • 국가별
  • 유럽 국가별 분석
    • 프랑스
    • 독일
    • 영국
    • 이탈리아
    • 스페인

제10장 아시아태평양의 혈액 악성 종양 검사 시장 전망

  • 시장 규모와 예측
    • 금액 기준
  • 시장 점유율과 예측
    • 컴포넌트별
    • 기술별
    • 치료 적응증별
    • 최종사용자별
    • 국가별
  • 아시아태평양 국가별 분석
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주

제11장 남미 혈액 악성 종양 검사 시장 전망

  • 시장 규모와 예측
    • 금액 기준
  • 시장 점유율과 예측
    • 컴포넌트별
    • 기술별
    • 치료 적응증별
    • 최종사용자별
    • 국가별
  • 남미의 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제12장 중동 및 아프리카 혈액 악성 종양 검사 시장 전망

  • 시장 규모와 예측
    • 금액 기준
  • 시장 점유율과 예측
    • 컴포넌트별
    • 기술별
    • 치료 적응증별
    • 최종사용자별
    • 국가별
  • MEA : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • UAE
    • 터키
    • 이집트

제13장 시장 역학

  • 성장 촉진요인
  • 과제

제14장 시장 동향과 개척

제15장 경쟁 상황

  • Abbott Laboratories, Inc.
  • Asuragen Inc.
  • Bio-Rad Laboratories, Inc.
  • Adaptive Biotechnologies Corporation
  • F.Hoffmann-La-Roche AG
  • Illumina, Inc.
  • ICON plc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Invivoscribe, Inc.

제16장 전략적 제안

ksm 23.07.04

The global hematologic malignancies testing market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors, including growing occurrences of blood cancer and extensive development in technology, are fueling the growth of the market. Hematologic malignancies are cancers that affect the blood, bone marrow, and lymph nodes. Leukemia, lymphoma, and myeloma are the common types of blood cancer. Hematologic malignancies testing is a medical testing method that helps to diagnose blood cancer. The other factors supporting the market's growth are a rise in R&D activities, increasing favorable government funding, rising emphasis on personalized medicine, increasing awareness among patients and healthcare professionals, rise in aging population base, growing adoption of inorganic growth strategies, an increasing number of product launches, and immense potential for emerging submarkets.

Increasing Occurrence of Blood-Related Disorders

The growing incidences of blood-related disorders, such as leukemia, lymphoma, and myeloma, are bolstering the growth of the market globally. According to the American Cancer Society, in the United States, around every 3 minutes, a person is diagnosed with leukemia, lymphoma, and myeloma. Owing to the rise in the number of patients who have hematologic cancer, the surge in the need for early detection and treatment of blood cancers is augmenting the growth of the market. Blood cancers are the fifth most common malignancy across the world and the second primary reason for cancer death. For instance, more than 300,000 people are diagnosed yearly with leukemia and 400,000 with lymphoma across the globe.

Technological Advancements and Rise in R&D Activities

The evolution of new technologies in the healthcare sector is surging the growth of the market. The increasing adoption of new innovative technologies, such as digital PCR, next-generation sequencing, cytogenetics, and others, is strengthening the growth of the market. The developments are helping to minimize the cost and time of treatment and improve the quality of human life. Moreover, the rise in R&D activities is propelling the growth of the market.

Increasing Adoption of Inorganic Growth Strategies

Growing inorganic growth strategies such as mergers, acquisitions, collaborations, partnerships, and an increasing number of product launches by market players are bolstering the growth of the market. For instance, in 2021, Natera, Inc., and Personalis, Inc. partnered in personalized oncology by coupling Personalis' NeXT tumor profiling and diagnostic products with Natera's personalized ctDNA platform Signatera for treatment monitoring and molecular residual disease assessment. Similarly, in 2018, Abbott launched an h-series incorporating a hematology system and has brought numerous changes in the clinical laboratories since then.

Market Segmentation

The global hematologic malignancies testing market is segmented into component, technique, therapeutic indication, end user, and company. Based on components, the market is divided into kits and services. Based on kits, the market is further divided into gene panels, molecular clonality testing, translocation testing, mutation testing, and others. Based on technique, the market is divided into next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in-situ hybridization (FISH), immunohistochemistry (IHC), and others. Based on therapeutic indication, the market is divided into leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and others. Based on end-user, the market is divided into hospitals & clinics, diagnostic laboratories, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising incidences of blood cancers in the country.

Market Players

Abbott Laboratories, Inc., Asuragen Inc., Bio-Rad Laboratories, Inc., Adaptive Biotechnologies Corporation, F.Hoffmann-La-Roche AG, Illumina, Inc., ICON plc., Invitae Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc. are some of the leading companies operating in the market.

Report Scope

In this report, global hematologic malignancies testing market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hematologic Malignancies Testing Market, By Component:

  • Kits
    • Gene Panels
    • Molecular Clonality Testing
    • Translocation Testing
    • Mutation Testing
    • Others
  • Services

Hematologic Malignancies Testing Market, By Component:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescence In-Situ Hybridization (FISH)
  • Immunohistochemistry (IHC)
  • Others

Hematologic Malignancies Testing Market, By Therapeutic Indication:

  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • Others

Hematologic Malignancies Testing Market, By End User:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutions
  • Others

Hematologic Malignancies Testing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Hematologic Malignancies Testing Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Hematologic Malignancies Testing Market

5. Voice of Customer

6. Clinical Trial Analysis

7. Global Hematologic Malignancies Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component (Kits v/s Services)
      • 7.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 7.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 7.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 7.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 7.2.5. By Company (2021)
    • 7.2.6. By Region
  • 7.3. Market Map

8. North America Hematologic Malignancies Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component (Kits v/s Services)
      • 8.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 8.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 8.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 8.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 8.2.5. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Hematologic Malignancies Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Technique
        • 8.3.1.2.3. By Therapeutic Indication
        • 8.3.1.2.4. By End User
    • 8.3.2. Canada Hematologic Malignancies Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Technique
        • 8.3.2.2.3. By Therapeutic Indication
        • 8.3.2.2.4. By End User
    • 8.3.3. Mexico Hematologic Malignancies Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Technique
        • 8.3.3.2.3. By Therapeutic Indication
        • 8.3.3.2.4. By End User

9. Europe Hematologic Malignancies Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component (Kits v/s Services)
      • 9.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 9.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 9.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 9.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 9.2.5. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Hematologic Malignancies Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Technique
        • 9.3.1.2.3. By Therapeutic Indication
        • 9.3.1.2.4. By End User
    • 9.3.2. Germany Hematologic Malignancies Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Technique
        • 9.3.2.2.3. By Therapeutic Indication
        • 9.3.2.2.4. By End User
    • 9.3.3. United Kingdom Hematologic Malignancies Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Technique
        • 9.3.3.2.3. By Therapeutic Indication
        • 9.3.3.2.4. By End User
    • 9.3.4. Italy Hematologic Malignancies Testing Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Component
        • 9.3.4.2.2. By Technique
        • 9.3.4.2.3. By Therapeutic Indication
        • 9.3.4.2.4. By End User
    • 9.3.5. Spain Hematologic Malignancies Testing Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Component
        • 9.3.5.2.2. By Technique
        • 9.3.5.2.3. By Therapeutic Indication
        • 9.3.5.2.4. By End User

10. Asia-Pacific Hematologic Malignancies Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component (Kits v/s Services)
      • 10.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 10.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 10.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 10.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 10.2.5. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Hematologic Malignancies Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Technique
        • 10.3.1.2.3. By Therapeutic Indication
        • 10.3.1.2.4. By End User
    • 10.3.2. India Hematologic Malignancies Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Technique
        • 10.3.2.2.3. By Therapeutic Indication
        • 10.3.2.2.4. By End User
    • 10.3.3. Japan Hematologic Malignancies Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Technique
        • 10.3.3.2.3. By Therapeutic Indication
        • 10.3.3.2.4. By End User
    • 10.3.4. South Korea Hematologic Malignancies Testing Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Component
        • 10.3.4.2.2. By Technique
        • 10.3.4.2.3. By Therapeutic Indication
        • 10.3.4.2.4. By End User
    • 10.3.5. Australia Hematologic Malignancies Testing Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Component
        • 10.3.5.2.2. By Technique
        • 10.3.5.2.3. By Therapeutic Indication
        • 10.3.5.2.4. By End User

11. South America Hematologic Malignancies Testing Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Component (Kits v/s Services)
      • 11.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 11.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 11.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 11.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 11.2.5. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Hematologic Malignancies Testing Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Component
        • 11.3.1.2.2. By Technique
        • 11.3.1.2.3. By Therapeutic Indication
        • 11.3.1.2.4. By End User
    • 11.3.2. Argentina Hematologic Malignancies Testing Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Component
        • 11.3.2.2.2. By Technique
        • 11.3.2.2.3. By Therapeutic Indication
        • 11.3.2.2.4. By End User
    • 11.3.3. Colombia Hematologic Malignancies Testing Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Component
        • 11.3.3.2.2. By Technique
        • 11.3.3.2.3. By Therapeutic Indication
        • 11.3.3.2.4. By End User

12. Middle East and Africa Hematologic Malignancies Testing Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Component (Kits v/s Services)
      • 12.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 12.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 12.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 12.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 12.2.5. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Hematologic Malignancies Testing Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Component
        • 12.3.1.2.2. By Technique
        • 12.3.1.2.3. By Therapeutic Indication
        • 12.3.1.2.4. By End User
    • 12.3.2. Saudi Arabia Hematologic Malignancies Testing Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Component
        • 12.3.2.2.2. By Technique
        • 12.3.2.2.3. By Therapeutic Indication
        • 12.3.2.2.4. By End User
    • 12.3.3. UAE Hematologic Malignancies Testing Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Component
        • 12.3.3.2.2. By Technique
        • 12.3.3.2.3. By Therapeutic Indication
        • 12.3.3.2.4. By End User
    • 12.3.4. Turkey Hematologic Malignancies Testing Market Outlook
      • 12.3.4.1. Market Size & Forecast
        • 12.3.4.1.1. By Value
      • 12.3.4.2. Market Share & Forecast
        • 12.3.4.2.1. By Component
        • 12.3.4.2.2. By Technique
        • 12.3.4.2.3. By Therapeutic Indication
        • 12.3.4.2.4. By End User
    • 12.3.5. Egypt Hematologic Malignancies Testing Market Outlook
      • 12.3.5.1. Market Size & Forecast
        • 12.3.5.1.1. By Value
      • 12.3.5.2. Market Share & Forecast
        • 12.3.5.2.1. By Component
        • 12.3.5.2.2. By Technique
        • 12.3.5.2.3. By Therapeutic Indication
        • 12.3.5.2.4. By End User

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape

  • 15.1. Abbott Laboratories, Inc.
  • 15.2. Asuragen Inc.
  • 15.3. Bio-Rad Laboratories, Inc.
  • 15.4. Adaptive Biotechnologies Corporation
  • 15.5. F.Hoffmann-La-Roche AG
  • 15.6. Illumina, Inc.
  • 15.7. ICON plc.
  • 15.8. Invitae Corporation
  • 15.9. Laboratory Corporation of America Holdings
  • 15.10. Invivoscribe, Inc.

16. Strategic Recommendations

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제